RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.

The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

Donald Trump touted his “energy dominance” agenda, claiming American oil production is up 600,000 barrels per day and the US ...

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...

Q4 2025 Earnings Call February 24, 2026 8:00 AM ESTCompany ParticipantsJeff Boyle - Vice President of Investor RelationsRandy Teel ...

Louisiana Attorney General Liz Murrill will argue in federal court in Lafayette Tuesday for an injunction to stop the FDA's ...

Pfizer (PFE) stock is in focus as the FDA grants full approval for its colorectal cancer drug Braftovi, developed with Ono Pharmaceutical (OPHLF). Read more here.

Using patent intelligence data from the FounderNest platform, Gonzalez highlights where small-molecule synthesis, formulation ...